Rapport Therapeutics Inc.
Clinical trials sponsored by Rapport Therapeutics Inc., explained in plain language.
A biopharmaceutical company developing precision medicines for neurological disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New epilepsy drug RAP-219 enters final testing phase
Disease control Recruiting nowThis study tests an experimental drug called RAP-219 in 333 adults with focal seizures (a type of epilepsy). The goal is to see if the drug safely reduces how often seizures happen compared to a placebo. Participants must be 18-75, have had focal epilepsy for at least 2 years, an…
Phase: PHASE3 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill aims to curb focal seizures in adults
Disease control Recruiting nowThis phase 3 study tests whether an investigational drug called RAP-219 can safely reduce the number of focal seizures in adults with epilepsy. About 312 participants will take either a low or medium dose of RAP-219 or a placebo pill daily. The main goal is to see if the drug low…
Phase: PHASE3 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for tough seizures: Long-Term safety trial launches
Disease control Recruiting nowThis study tests the long-term safety of an experimental drug called RAP-219 in 30 adults whose focal seizures do not respond well to current treatments. Participants must have already completed a related earlier study. The goal is to see if RAP-219 remains safe and helps reduce …
Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC